The Elecsys CA 15-3 II assay is a diagnostic test offered by Roche Diagnostics. It is used for the quantitative measurement of cancer antigen 15-3 (CA 15-3) levels in human serum or plasma samples.
CA 15-3 is a tumor marker that is often elevated in breast cancer and other types of cancers, although it is not specific to breast cancer and can be elevated in other conditions as well. The Elecsys CA 15-3 II assay provides clinicians with a tool to monitor disease progression and treatment response in patients with breast cancer.
The assay utilizes an electrochemiluminescence immunoassay (ECLIA) technology. It is performed on Roche Elecsys immunoassay analyzers, which are automated systems used in clinical laboratories.
The Elecsys CA 15-3 II assay provides accurate and reliable quantitative results for CA 15-3 levels, aiding in the management and monitoring of breast cancer patients. Changes in CA 15-3 levels over time can provide valuable information about the effectiveness of treatment and the progression of the disease.
It’s important to note that the Elecsys CA 15-3 II assay is not used for screening or diagnosis of breast cancer. It is primarily used as a monitoring tool in conjunction with other clinical assessments.
If you have any specific questions or need further information about the Elecsys CA 15-3 II assay, I recommend referring to the product documentation or contacting Roche Diagnostics directly for the most accurate and up-to-date information.
Sem massa mattis sem, at interdum magna augue eget diam. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Morbi lacinia molestie dui. Praesent blandit dolor. Suspendisse potenti. Nunc feugiat mi a tellus consequat imperdiet. Vestibulum sapien. Proin quam. Etiam ultrices. Suspendisse in justo eu magna luctus suscipit. Sed lectus. Integer euismod lacus luctus magna. Quisque cursus, metus vitae pharetra auctor,
Morbi lectus risus, iaculis vel, suscipit quis, luctus non, massa. Fusce ac turpis quis ligula lacinia aliquet. Mauris ipsum. Nulla metus metus, ullamcorper vel, tincidunt sed, euismod in, nibh. Quisque volutpat condimentum velit. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nam nec ante.